Pharmalot.. Pharmalittle.. As the weekend nears.. we’re catching up on Valeant and..
And so, another working week is about to draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. To be honest, our agenda is rather modest. We hope to manicure the Pharmalot grounds, indulge our shortest of short people and catch up on some reading. And what about you? This is a lovely time of year to enjoy the great outdoors. You know, picking apples and that sort of thing. You could plan an end-of-year getaway. Or maybe reach out to someone special. Whatever you do, have a grand time, but be safe. See you soon…
Valeant Pharmaceuticals will hold an investor briefing on Monday to refute reports about its accounting that “contain numerous errors, unsupported speculation and incorrect interpretations of facts;” Speedier diagnostics that can distinguish between bacterial and viral infections are needed to combat unnecessary prescriptions for antibiotics, according to a report by the Review on Antimicrobial Resistance; and The latest biotechnology stock-market debut, Dimension Therapeutics, floundered yesterday, illustrating how the squeeze in new issues persists for one of the hottest segments of the initial public offering market.